window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 6, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Drug Discovery & Development

  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Efzimfotase alfa shows mixed Phase 3 results in hypophosphatasia across pediatric and adult patients

    Efzimfotase alfa has shown positive Phase 3 results in children [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Therapeutic Areas

    ImmuneOncia Therapeutics and Lonza agree manufacturing partnership for PD-L1 antibody Danburstotug

    ImmuneOncia Therapeutics and Lonza have entered into a manufacturing collaboration [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    UMass Chan, Caring Cross and Trenchant BioSystems form sickle cell gene therapy manufacturing alliance

    UMass Chan Medical School, Caring Cross and Trenchant BioSystems have [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    BridgeBio submits FDA NDA for BBP-418 in limb-girdle muscular dystrophy type 2I/R9

    BridgeBio Pharma has submitted a New Drug Application (NDA) to [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    Symeres and Ambagon partner on molecular glue research in colorectal cancer

    Symeres and Ambagon Therapeutics are collaborating to evaluate molecular glues [...]

    May 5, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development

    Insilico Medicine signs $2.75bn AI drug discovery deal with Eli Lilly

    Insilico Medicine has signed a drug discovery collaboration with Eli [...]

    May 5, 2026
  • Central Nervous System,Drug Discovery & Development,Therapeutic Areas

    Strategies to extend ketamine antidepressant effects identified in new study

    Researchers have identified a molecular target that could extend the [...]

    May 5, 2026
  • Digital & Data,Drug Discovery & Development,Therapeutic Areas

    Bullfrog AI signs commercial agreement with top 5 global pharma company to identify novel target in major depressive disorder

    BullFrog AI Holdings has entered a commercial agreement with a [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Delivery & Formulation,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Bio-Sourcing and Tiny Cargo partner to develop oral monoclonal antibodies using milk exosomes

    Bio-Sourcing and Tiny Cargo will develop oral monoclonal antibody therapies [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Levicept reports Phase 2 osteoarthritis data in The Lancet showing pain reduction with LEVI-04

    Levicept has reported Phase 2 clinical trial results for LEVI-04 [...]

    May 5, 2026
Previous456Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Currax highlights peer-reviewed review supporting combination approaches in obesity treatment
    Categories: Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • MaaT Pharma publishes real-world CHRONOS data in third-line acute GvHD
    Categories: Clinical & Regulatory, Drug Discovery & Development, Therapeutic Areas
  • Symbiosis expands QC capabilities with new 30°C stability chamber
    Categories: Manufacturing & Supply Chain, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top